Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol. by Hill, M et al.
Hill et al. BMC Pregnancy and Childbirth 2014, 14:229
http://www.biomedcentral.com/1471-2393/14/229STUDY PROTOCOL Open AccessEvaluation of non-invasive prenatal testing (NIPT)
for aneuploidy in an NHS setting: a reliable
accurate prenatal non-invasive diagnosis (RAPID)
protocol
Melissa Hill1,2, David Wright3, Rebecca Daley1,4, Celine Lewis1,2, Fiona McKay1, Sarah Mason1, Nicholas Lench1,
Abigail Howarth1, Christopher Boustred1, Kitty Lo5, Vincent Plagnol5, Kevin Spencer6, Jane Fisher7, Mark Kroese8,
Stephen Morris9 and Lyn S Chitty1,2,4*Abstract
Background: Non-invasive prenatal testing (NIPT) for aneuploidies is now available through commercial companies
in many countries, including through private practice in the United Kingdom (UK). Thorough evaluation of service
delivery requirements are needed to facilitate NIPT being offered more widely within state funded healthcare
systems such as the UK’s National Health Service (NHS). Successful implementation will require the development of
laboratory standards, consideration of stakeholder views, an analysis of costs and development of patient and
health professional educational materials.
Methods/Design: NIPT will be offered in an NHS setting as a contingent screening test. Pregnant woman will be
recruited through six maternity units in England and Scotland. Women eligible for Down’s syndrome screening
(DSS) will be informed about the study at the time of booking. Women that choose routine DSS will be offered
NIPT if they have a screening risk ≥1:1000. NIPT results for trisomy 21, 18, 13 will be reported within 7–10 working
days. Data on DSS, NIPT and invasive testing uptake, pregnancy outcomes and test efficacy will be collected.
Additional data will be gathered though questionnaires to a) determine acceptability to patients and health
professionals, b) evaluate patient and health professional education, c) assess informed choice in women accepting
or declining testing and d) gauge family expenses. Qualitative interviews will also be conducted with a sub-set of
participating women and health professionals.
Discussion: The results of this study will make a significant contribution to policy decisions around the
implementation of NIPT for aneuploidies within the UK NHS. The laboratory standards for testing and reporting,
education materials and counselling strategies developed as part of the study are likely to underpin the
introduction of NIPT into NHS practice.
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In England, Scotland and Wales the National Screening
Committee (NSC) recommends that Down’s syndrome
screening (DSS) is offered to all pregnant women. The
combined screening test (CST), which uses both fetal
ultrasound and maternal serum biomarkers to generate
a risk assessment, is performed between 10 and 14 +
1 weeks gestation and has a detection rate of around
85% and a false positive rate of 2.5% when the risk cut
off is 1:150. The quadruple test, which uses only mater-
nal serum biomarkers, is performed between 14 + 2 and
20 weeks gestation and has a detection rate of around
70% and a false positive rate of 3.5% when the risk cut
off is 1:150. In current NHS practice women who have a
screening risk of 1:150 or greater are offered invasive
prenatal diagnosis (IPD), either chorionic villus sampling
(CVS) from 11 weeks or amniocentesis from 15 weeks,
that will give a definitive diagnosis of Down’s syndrome
(trisomy 21) or one of the other common aneuploidies
(trisomy 18 and trisomy 13). Other chromosomal abnor-
malities may be detected with IPD if full karyotyping or
microarray analysis is performed.
As invasive tests carry a risk of miscarriage of around
0.5% [1], researchers have long been focused on develop-
ing an alternative, highly accurate non-invasive ap-
proach. The possibility of diagnosing aneuploidies with a
maternal blood test emerged with the discovery of cell
free fetal DNA (cffDNA) in 1997 [2], and in 2008 the
first proof-of-principle studies were published showing
that non-invasive prenatal testing (NIPT) for aneuploidy
was possible using next generation sequencing (NGS)
[3,4]. NGS technology has advanced rapidly and NIPT
for Down’s syndrome now has detection rates above 99%
and false positive rates of 0.1-1% [5-10]. Detection rates
from validation studies are also high for trisomy 18
(>97%) [10-14] and trisomy 13 (up to 90%) [10,11,13]
and continue to improve [15,16]. The small false positive
rate means that NIPT is not considered fully diagnostic
and IPD is recommended to confirm a positive NIPT re-
sult [17-19]. There may be further scope for using NIPT
for identifying other chromosomal abnormalities as NGS
has been reported to detect other chromosomal rear-
rangements and molecular karyotyping with NIPT now
seems feasible, although the limits of detection and false
positive rates are yet to be determined [20-22].
NIPT for Down’s syndrome was first launched through
commercial providers in the USA and China/Hong Kong
in 2011. These commercial tests are now also available
in Europe, including through private practice in the UK,
where samples are sent for testing in the USA or Hong
Kong. However, NIPT is not yet being offered within a
state funded healthcare system such as the NHS. The
RAPID (Reliable, Accurate Prenatal, non-Invasive Diag-
nosis) research programme (RP-PG-10107-0707) wasestablished to investigate all aspects of implementing
non-invasive tests based on cffDNA into the NHS [23].
Before NIPT for aneuploidy can be implemented into
routine clinical practice within the NHS, further infor-
mation is required to determine where it fits in the care
pathway, uptake in clinical practice, whether the rate of
invasive testing will change, the costs for the NHS and
for service users, and how best to educate women and
health professionals. There is information available to
address some of these questions based on hypothetical
scenarios [24-31] and research reporting NIPT uptake
and experience outside the UK is beginning to appear
[32]. However, to get a true understanding of how NIPT
for aneuploidy would work best within the NHS DSS
programme, it is important to thoroughly evaluate NIPT
within this setting. This will allow delivery of a compre-
hensive assessment that includes laboratory require-
ments, test performance, cost considerations and service
user and provider needs, preferences and opinions.
There are several possible approaches for introducing
NIPT into the current NHS DSS programme [24]. The
three most likely are;
1. An alternative to IPD, where NIPT is only offered to
women with a high risk result.
2. A first line screening test to replace the current DSS
programme.
3. Contingent screening, where all women with a DSS
risk above a pre-specified level are offered NIPT.
Using NIPT as an alternative to IPD in the current
care pathway, would result in a slight decrease in the
number of Down’s syndrome cases detected and, as dis-
cussed above, IPD would still be required for confirm-
ation of abnormal results. Recent modelling of costs in
an NHS setting has shown that if NIPT were used as a
first line screening test that replaced the current DSS
programme there would be benefits in terms of cases de-
tected and a reduction miscarriages resulting from inva-
sive tests. However, this approach would be much more
expensive than current DSS, even if the cost of NIPT
was very low [33]. Another disadvantage of this ap-
proach is that potential additional benefits conferred by
current DSS would be lost, including early identification
of other fetal abnormalities and pregnancies at risk of
preeclampsia and intrauterine growth restriction (IUGR)
[34]. Offering NIPT using a contingent approach will
provide the same or better outcomes as current DSS in
terms of cases detected, have fewer procedure-related
miscarriages and be less costly than the current screening
pathway [33]. Further, it would be possible to adjust
screening cut-off levels in order to stay within the existing
DSS budget if necessary. For these reasons, in this study
NIPT will be included in the current DSS care pathway as
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women who choose to have DSS and have a screening re-
sult of 1:1000 or greater. The cut-off of 1:1000 is expected
to provide a good balance between the cost of the test, im-
proving detection of Down’s syndrome cases and decreas-
ing the number of invasive tests performed [24,33].
The benefits of contingent screening could be en-
hanced further if the accuracy of the initial DSS tests
were improved as fewer NIPT tests would be needed.
The current DSS tests include the measurement of two
maternal serum biomarkers in the first trimester (PAPP-
A and free-beta-hCG) and four in the second trimester
(alphafeto-protein (AFP), inhibin-A, oestriol and free-
beta-hCG or total hCG). Recently it has been reported
that the addition of other biomarkers, for example AFP
and placental growth factor (PlGF) to the first trimester
test has the potential to improve the detection of Down’s
syndrome pregnancies and may also help identify preg-
nancies at high risk of other adverse pregnancy out-
comes (preeclampsia and intra-uterine fetal growth
restriction) [35,36]. As part of this study we will measure
additional maternal serum biomarkers, including AFP
and PIGF, in women undergoing DSS at a subset of par-
ticipating hospitals. These data will then be used with
the currently measured markers to examine multiple al-
gorithms for evaluating the risk of Down’s syndrome
and explore whether or not these markers can accurately
predict other adverse pregnancy outcomes.
Thorough evaluation of implementation strategies for
NIPT requires approaches that not only examine laboratory
performance and test uptake but also consider psychosocial
issues, educational material and health economic data.
While the prospect of a test that is available earlier in preg-
nancy and does not place the fetus at risk is welcomed by
many potential service users [27,29,37], there are significant
concerns around how this should happen in order to pre-
vent the potential for testing to become routine and to
maintain informed choice [38-41]. Furthermore, we have
shown that there are significant differences in the values
women and health professionals place on aspects of NIPT
and how it should be offered [26]. There are also divergent
views about some ethical aspects of delivery of NIPT, for
example, the need for written consent and for time for re-
flection between information-giving and consenting to the
test, and concerns over pressure to undergo testing if the
risk of miscarriage is removed [27,41]. These aspects will be
investigated in this study to enable us to make evidence-
based recommendations about best practice.
Another significant consideration for implementation
is cost. Currently NIPT is offered at £400-£750 in the
UK, which includes the cost of sending samples overseas
for analysis. Accurate and detailed costing under NHS
clinical practice conditions is likely to be an important
factor affecting widespread adoption of NIPT. In orderto deliver a reliable economic evaluation, an accurate es-
timate of uptake of NIPT and the effect of introducing
NIPT on the uptake of both DSS and any subsequent
IPD is required. Work presenting hypothetical scenarios
to women suggests that the uptake of DSS is likely to in-
crease with the implementation of NIPT [27] and emer-
ging evidence from offering the test in the USA shows
fewer women turn down follow-up testing after a high
risk screening result following the introduction of NIPT
[32]. However, the impact of introducing NIPT into the
NHS DSS programme will not be clear until evaluated in
a ‘real-life’ situation.Aims and objectives
The overall aim of the study is to evaluate service deliv-
ery requirements for the implementation of NIPT for
aneuploidies within the NHS.Principal objectives
 Identify the main barriers and facilitators for
implementing NIPT within the NHS
 Collect data that could be used to evaluate NIPT in
NHS clinical practice
 Evaluate patient uptake and experience of NIPT for
Down’s syndromeSecondary objectives
 Collect data that could be used to improve current
DSS and prediction of adverse pregnancy outcomes
 Pilot and evaluate health professional education
materials
 Pilot and evaluate patient information materials
 Explore the acceptability of NIPT to service users
including acceptability as a contingent screening test
and as an assessment of informed choice
 Compare uptake of screening, NIPT and invasive
testing. Including an evaluation of any differences
related to ethnicity, parity, age and other routinely
collected parameters
 Perform a detailed health economic evaluation
 Confirm the sensitivity and specificity of NIPT in an
intermediate risk populationMethods/Design
Ethical approval
This study forms part of the RAPID programme which
is evaluating standards for the implementation of non-
invasive testing based on cffDNA in the UK NHS [23].
NHS Research Ethics Committee approval for the study
has been obtained (13/LO/0082).
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This is a multi-centre observational study. Figure 1 pro-
vides an overview of how the study fits within the current
clinical care pathway.
Population
Women will be recruited from 6 maternity units in
England and Scotland, which together have around 32500
births annually. The selected maternity units includeFigure 1 Overview of study protocol and the relationship with the cliDistrict General and Teaching Hospitals, in both urban
and rural areas and encompass a wide ethnic and social
mix. In addition there is a wide variation in uptake of
current DSS at these trusts (56.5-93%) and IPD in
screen positive women (50–85.4%). The pathway for de-
livering DSS varies and includes one-stop clinics and
two-stage pathways which include scanning and blood
draw performed at one appointment followed by a
phone call on another day with results.nical care pathway.
Hill et al. BMC Pregnancy and Childbirth 2014, 14:229 Page 5 of 10
http://www.biomedcentral.com/1471-2393/14/229Sample size
The overall study sample size was justified on the preci-
sion achieved for the differences in overall detection rate
and false positive rate between the existing DSS pathway
and the new contingent NIPT pathway. A screened sam-
ple of 25,000 will enable the reduction in false positive
rate with the contingent pathway compared to the exist-
ing pathway to be estimated to within ±0.2%. With an
anticipated reduction of 2.4% or higher, this corresponds
to a 95% confidence interval extending from 2.2% to
2.6%. This sample size will enable us to estimate the in-
crease in detection rate to within ±0.65%. With an antic-
ipated increase in detection rate of at least 8%, this
corresponds to a 95% confidence interval ranging from
1.5% to 14.5%, thus enabling us to confirm the increased
detection rate with the contingent pathway. Although
not all women take up DSS, recruitment in 6 units with
total annually bookings of more than 32,500 will allow
us to achieve the required sample size.
This total population and number of units is also required
to allow us to evaluate change in the uptake of both screen-
ing and diagnostic testing so as to get a robust estimate of
change that will inform a detailed economic analysis.
The biomarker analysis will be conducted in three
units with combined annual bookings of approximately
20000. The potential sample size of 18,000 pregnancies
(assuming not all women accept DSS) has sufficient
power to detect an effect given the prevalence of severe
preeclampsia of around 1:200 pregnancies.
Inclusion criteria
Inclusion criteria for this study are: pregnant women
who book before 20 weeks gestation who accept DSS as
part of routine care; older than 16 years; able to read
and understand English and provide informed consent;
non-English speakers where there is a trained interpreter
available as part of the routine clinical service.
Exclusion criteria
Exclusion criteria for this study are: women booking after
20 weeks; younger than 16 years; women who declined
DSS; women with multiple pregnancies and those who are
unable to understand the participant information sheet
because English is not their first language.
Recruitment
Prior to the start of the study an education package for
health professionals that includes face-to-face training and
written information will be delivered at each participating
maternity unit. Every pregnant woman who books at a
participating hospital and is eligible for DSS will be in-
formed about the study through a participant information
sheet sent with her booking appointment details and brief
discussion of the study with the midwife during herbooking appointment. Women who choose to take up
DSS will have the standard DSS test appropriate for their
gestation. At three of the participating hospitals, women
having DSS will be asked for their permission to use the
excess serum for research to evaluate potential improve-
ments in the current DSS test. The results of the extra
marker analysis will not be reported in the current preg-
nancy, but will be used for modelling of new approaches
for estimating risk. At all participating hospitals, women
with a risk of 1:1000 or greater for trisomy 21, 18 or 13
will be offered the opportunity to discuss options for fur-
ther testing. Standard local protocols for delivering DSS
results will be followed and consent for participation in
the study obtained. If the risk is 1:1000 to 1:151, the mid-
wife will explain the DSS result and the study, check un-
derstanding and, if consent is given, take blood for NIPT.
If the risk is ≥1:150, the midwife will discuss IPD, as is
current standard practice at this risk, and NIPT including
the benefits and limitations of both tests. If consent is
given, women in this risk category can choose to have in-
vasive testing or NIPT, but for those choosing IPD we will
also seek consent for NIPT.
Delivery of NIPT results
NIPT results for trisomy 21, 18 and 13 will be reported.
The samples from women who also had an ultrasound
abnormality or NT measurement of ≥3.5 mm will also
receive a result for Turner syndrome (Monosomy X).
Women will be phoned with their NIPT results as soon
as available, and at most within 7–10 working days of
taking blood.
Predicted to be affected
 Women will be advised that whilst the likelihood is
high that the result is correct (99%), as there is a
small false positive rate (<1:100), IPD for
confirmation is recommended.
Highly unlikely to be affected
 For women with a DSS result of 1:1000 to 1:151, the
midwife will explain that this is reassuring and
confirms her low risk result (1:10000).
 For women with a DSS result of ≥1:150 who have not
already had an invasive test, the midwife will explain
that this is a reassuring result as data indicate that the
NIPT test is >99% accurate, but offer IPD for
confirmation should the woman wish it.
Inconclusive NIPT result
 Women with a DSS result of 1:1000 to 1:151 will be
told that as this is a new test we occasionally get an
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offered a repeat NIPT test.
 Women with a DSS result of ≥1:150 who have not
already had IPD, will be offered repeat NIPT or IPD.
Biomarker analysis
Up to 1 ml of excess serum from the standard DSS sam-
ple will be used for biomarker analysis at the clinical
biochemistry laboratory at Barking, Havering & Red-
bridge University Hospitals NHS Trust, using standard
immunoassay procedures. These data will be used with
currently measured markers to explore multiple algo-
rithms for the evaluation of risk of Down’s syndrome,
but will also be correlated with other adverse pregnancy
outcomes to determine whether or not these markers
accurately predict other adverse pregnancy outcomes.
NIPT testing
Maternal blood will be taken into EDTA tubes or, when
there will be delay of more than 8 hours in transferring
samples, into cell free DNA (cfDNA) blood collection
tubes and sent to the laboratory. Blood will be centrifuged
and cfDNA extracted from maternal plasma using the
QIAsymphony (Qiagen, Netherlands) in the North East
Thames Regional Genetics (NETRGL). Any remaining
plasma and the blood cell pellets will be stored at −80°C
for quality assurance purposes and further analysis until
the pregnancy outcome is known.
Pooled patient libraries will be prepared and subjected
to NGS (Illumina HiSeq 2500) at NETRGL using estab-
lished protocols. Bioinformatic analysis of NGS data will
be conducted using the RAPIDR package (http://cran.
r-project.org/web/packages/RAPIDR/), developed in-
house [42] and a result assigned to each patient. NGS
libraries will be stored at −20°C until the pregnancy
outcome is known for future use if repeat NGS testing
is required.
NIPT Validation
To provide benchmarking of NIPT performed in a CPA
accredited lab (GOSH) we are collaborating with a com-
mercial provider, Illumina, with experience of several
thousand tests. Four hundred samples will be sent for
testing with the Verifi® prenatal test [43], which detects
the major trisomies and sex chromosome abnormalities if
requested. If there is a discrepancy in the results from the
NHS and Illumina laboratories, the result will be treated
as “inconclusive” and the participant will be offered a
repeat NIPT test or an invasive test as appropriate.
Prenatal data collection and analysis
Uptake of DSS and invasive testing in women with DSS
results ≥1:150 will be evaluated at all participating sites
prior to offering NIPT. Following the introduction ofNIPT, data on uptake of DSS, NIPT and IPD and NHS
costs will be collected. Prenatal data collected will in-
clude routinely collected demographics and pregnancy
details, including DSS results with absolute values and
MoMs, crown-rump length, nuchal translucency meas-
urement. Results of any IPD tests (qfPCR, full karyotype
or microarray) will be obtained. In the event of preg-
nancy loss without IPD, results of any cytogenetic ana-
lysis of products of conception, placenta or skin will be
obtained. We will collect pregnancy outcome data for all
participants, this will include liaison with the local cyto-
genetics laboratories and the National Down’s Syndrome
Cytogenetic Register to determine all cases of aneuploidy
reported but not detected by NIPT in our cohort.
The characteristics of the study sample, including up-
take, will be summarised graphically and in tables. Point
and interval estimates (95% confidence intervals) will be
produced for the following;
1. The overall and age-specific detection rates (DR)
and false positive rates (FPR) of the combined test
with risk cut-off of 1:150
2. Overall and age-specific rates of continuation (risks
of 1:1000 or higher) to NIPT
3. The DR and FPR for contingent policies in which
women with risks in of 1:1000 or higher are given
NIPT
4. The differences in DR and FPR from between (1)
and (3)
5. Change in uptake rates for DSS and IPD
Confidence intervals will be obtained using bootstrap-
ping. The bootstrap samples will also be used to provide
interval estimates for the health economic assessment.
Analysis will be conducted using the R statistical software.
This will be pre-specified in a detailed Statistical Analysis
Plan (SAP) containing listings of all programmes that will
be validated and reviewed independently.
We will also compare the uptake of DSS, NIPT and
IPD and evaluate any differences related to ethnicity,
parity, age and other routinely collected characteristics.
Health economic evaluation
The economic analysis will assess the cost implications
of implementing NIPT, including accounting for changes
in uptake compared with the current system.
We will:
1. Delineate the two pathways for DSS: (1) the current
pathway; and (2) a new pathway using NIPT as
contingent screening.
2. Use data collected from local study sites to plot
movement of pregnant women through the
pathways, including accounting for differences in
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scans, counselling, laboratory tests, NIPT uptake,
number of diagnostic tests and pregnancy outcomes.
Of particular importance is the avoidance of IPD,
which will be accounted for in the analysis.
3. Identify unit costs associated with the main cost
components of the diagnosis pathways from routine
published sources and market prices, including the
costs of NIPT.
4. Investigate the mean cost per pregnancy of the
current and new DSS pathway including contingent
NIPT.
5. Investigate the cost impact of reorganising laboratory
services away from IPD to NIPT, including capital
investment and staff retraining costs.
6. Analyse the expected budget impact to the NHS of
implementing NIPT as contingent screening versus
the current screening pathway based on the mean
incremental costs per woman tested and the
expected number of women tested.
The perspective of the analysis will be the NHS. While
incremental personal and social services costs are com-
monly included in economic evaluations these are likely
to be zero in this study and so will be omitted. The time
horizon for the analysis is the time period from the start
of pregnancy until the end of pregnancy. The units of
analysis are the pregnancy, eg, we will calculate the
mean cost per pregnancy using NIPT.
To investigate additional costs to families we will ask a
subset of women (approximately N = 400) before and after
the introduction of NIPT to complete a short question-
naire to ascertain how their use of NHS and other services
has been affected by the implementation of NIPT. The
questionnaire will ask women to report contacts with the
charitable and private sectors, time off work for them-
selves or their families, and out-of-pocket expenses. The
women approached to complete a questionnaire both be-
fore and after the introduction of NIPT will comprise: (1)
women who declined DSS; (2) women whose DSS result
was <1:1000; (3) women whose DSS result was between
1:1000–151; and (4) women with a risk ≥1:150.
Evaluation of health professional education material
A face-to-face training session and information sheets
have been developed to educate health professionals in-
volved in discussing and offering NIPT. This approach
will be evaluated and the results used to develop other
teaching materials, available via e-learning and mobile
apps. Training will be delivered by the research team in
conjunction with Antenatal Results and Choices (ARC), a
patient charity experienced in training health professionals
in prenatal counselling. Two to three group training ses-
sions will be offered in each maternity unit, with asubsequent cascade approach used to ensure complete
coverage. This cascade approach is recommended by
the NSC and widely used in England for delivering ante-
natal screening education.
Educational sessions will be evaluated using a multi-
stage approach, comprising three surveys:
1. Pre-course survey – including demographics,
confidence in discussing and offering NIPT,
self-perceived knowledge of NIPT.
2. Immediate post-course survey - learners’ perceptions
of the session with open questions exploring useful
aspects and any suggested changes or
improvements.
3. A post-course survey to explore knowledge and
experience of NIPT.
In addition, focus groups or interviews will be con-
ducted with approximately 20 course attendees to deter-
mine any impact on clinical practice and areas of unmet
need that should be addressed in future courses.
Evaluation of patient information
A patient information leaflet describing NIPT for aneu-
ploidy has been developed based on previous work in
RAPID [44]. Action research methodology will be used
to evaluate the patient information leaflet with a short
questionnaire. Results will be used to refine and improve
the patient information.
Evaluation of stakeholder views
A mixed methods approach will be adopted to eva-
luate stakeholder attitudes towards implementation of
NIPT to elicit potential barriers to and facilitators for
implementation.
1. Women who have been offered NIPT
To explore the views and experiences of women who
have been offered NIPT as part of the study a mixed
methods study including a questionnaire and interviews
at two time points will be conducted. Time 1 (T1) = after
accepting (or declining NIPT), after blood has been
taken but prior to receiving test results; Time 2 (T2) =
one month following receipt of test results. All women
who accept or decline NIPT will be invited to complete
both questionnaires. A subset will also be invited to take
part in a telephone or face-to-face interview.
The T1 questionnaire comprises a number of validated
psychological measures; the Multi-dimensional Model of
Informed Choice (MMIC) [45], the Deliberation scale
[46], the Decisional Conflict scale [47,48], and the State-
Trait Anxiety Inventory [49]. Questions addressing their
reasons for accepting or declining NIPT and a number
Hill et al. BMC Pregnancy and Childbirth 2014, 14:229 Page 8 of 10
http://www.biomedcentral.com/1471-2393/14/229of demographic questions will also be included. The T2
questionnaire includes the Decisional Regret scale [50]
and the State-Trait Anxiety Inventory [49]. Questions
addressing the outcome of their NIPT test and resulting
actions will also be included.
At T1 a subset of women with varying demographic
backgrounds, previous experiences of pregnancy and
screening risk results will be invited to take part in an
interview to explore knowledge and attitudes towards
NIPT, factors influencing decision-making, motivation for
testing and the decision-making process including deliber-
ation, pre-test counselling and support. At T2 a similarly
diverse subset of women, including women with positive
and negative NIPT outcomes, will be invited to take part
in an interview to reflect on their decision, explore their
views on NIPT, discuss service delivery and their overall
experience of taking part in the evaluation study.
2. Health professionals working in participating
maternity units and other professionals, including
healthcare managers and laboratory staff.
Health professionals from participating units will be
invited to take part in qualitative interviews to discuss
their experience of offering NIPT as part of their clinical
service. Other stakeholders will be invited to explore their
views on introducing NIPT into an NHS clinical service.
For all interviews we will follow the accepted ap-
proach for recruiting in qualitative research whereby in-
terviews will continue until no new codes or themes are
emerging and saturation is reached [51]. From previous
experience we would anticipate that this is generally
20–40 interviews [44,52,53]. Interviews will be con-
ducted in person or by phone, will last approximately
30–45 minutes, and be audiotaped and transcribed ver-
batim. To maintain confidentiality, participants will be
assigned a pseudonym. Interview data will be analysed
using thematic analysis [51].
Ultimately this arm of the study will be used to inform
the further development of the patient and health pro-
fessional information materials, public education and de-
velopment of implementation strategies.
Discussion
The overarching goal of this study is to evaluate NIPT
for aneuploidy in an NHS setting. This will allow us to
provide the NSC with data on the uptake of DSS, NIPT
and IPD, NHS and patient costs and acceptability to ser-
vice users and providers. This data can then inform NSC
in its considerations on whether NIPT should to be in-
cluded in the DSS programme. Hence, the main potential
outcome of this research is that it will have instigated and
supported the implementation of NIPT as contingent
screening in the NHS. If this happens, it will result in saferprenatal testing for aneuploidies by reducing the number
of invasive tests required. Importantly it will also serve to
negate the current inequality of access that results from
NIPT only being available privately. The laboratory
standards for testing and reporting, education materials
and guidelines for best practice developed as part of the
study will underpin the implementation of NIPT into
NHS services.
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